Fate Therapeutics, Inc. · NASDAQ:FATE
Fate Therapeutics — Investor Presentation (August 2023)
36 slides from Fate Therapeutics's investor presentation, August 2023
Slide 1: Better Cells For Better Therapies: Programmed Cellular Immunotherapies
Better Cells For Better Therapies™ Programmed Cellular Immunotherapies Transforming the Treatment of Cancer and Autoimmune Diseases with Off-the-shelf, Multiplexed-engineered, iPSC-derived Cellular Immunotherapy August 2023 -1-
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the safety and therapeutic potential of the Company’s product candidates, the advancement of and plans and tim
Slide 3: Changing the Game in Cell Therapy
Changing the Game in Cell Therapy Transforming the Cell Therapy Field with a Drug-like Product Paradigm Multiplexed Engineering Multiple mechanisms of attack against cancer incorporated into cell product Drug-like Treatment Mass Production Multi-dose schedules administered Scalable GMP operations yi
Slide 4: Changing the Game in Cell Therapy: Making Cell Therapy Look Like Monoclonal Antibody Therapy
Changing the Game in Cell Therapy To Make Cell Therapy Look Like Monoclonal Antibody Therapy • Highly characterized drug product Drug-like Cell • Large-scale production with low unit cost Product • Cryopreserved for long-term storage in inventory • Off-the-shelf availability Broad Patient • Well-tol
Slide 5: Disruptive iPSC Product Platform
Disruptive iPSC Product Platform Creating Multiplexed-engineered iPSC-derived Cell Products A Single Human Induced Pluripotent Stem Cell (iPSC) A renewable source for mass production of cell products Unlimited Clonal Single iPSC Clone Potential to Differentiate Expansion into 200+ Cell Types Multipl
Slide 6: Disruptive iPSC Product Platform: Mass Production of Cell Products
Disruptive iPSC Product Platform Mass Production of Multiplexed-engineered Cell Products for Off-the-shelf Patient Treatment Off-the-shelf, On-demand Treatment in Outpatient Setting Multiplexed engineering to incorporate multiple MOAs Clonal master iPSC bank to mass produce uniform and well-characte
Slide 7: First-in-class Cell Product Pipeline
First-in-class Cell Product Pipeline Multiplexed-engineered, iPSC-derived CAR NK Cell and CAR T-cell Product Candidates Program (Cell Type) Indication CAR Target(s) Research Preclinical Phase 1 Partner Oncology FT576 (iNK) Multiple Myeloma BCMA FT522 (iNK) B-cell Lymphoma CD19, 41BB FT819 (iT) B-cel
Slide 8: Integrated Technology Operations
Integrated Technology Operations Advanced Manufacturing Capabilities to Provide Clinical and Early Commercial Supply Launch of primary in-house GMP facility (Poway, CA) • 40,000 SF cGMP cell manufacturing facility co-located with corporate headquarters • Launched in 3Q22 with end-to-end capabilities
Slide 9: iPSC-derived CAR NK Cell Programs for Cancer
iPSC-derived CAR NK Cell Programs for Cancer -9-
Slide 10: FT576: Multi-antigen Targeted CAR NK Cell Product Candidate
FT576: Multi-antigen Targeted CAR NK Cell Product Candidate Targeting BCMA and CD38 for Multiple Myeloma hnCD16 Multi-antigen targeting • BCMA: CAR construct with novel binding domain targeting BCMA; CD38-targeted designed to trigger target cell lysis at low expression levels monoclonal antibody CAR
Slide 11: FT576: CD38-targeted mAb Combination to Mitigate Allo-rejection
FT576: Multi-antigen Targeted CAR NK Cell Product Candidate CD38-targeted mAb Combination to Mitigate Allo-rejection and Promote Functional Persistence • FT576 combination with CD38-targeted mAb therapy is designed to confer multiple therapeutic advantages, including mitigating allo-rejection throug
Slide 12: FT576: Single-dose, Low-dose Administration Shows Early Anti-Myeloma Activity
FT576: Multi-antigen Targeted CAR NK Cell Product Candidate Single-dose, Low-dose Administration Shows Early Evidence of Anti-Myeloma Activity Safety • No DLTs, and no events of any grade of CRS, ICANS, or GvHD Oct 7, 2022 were observed. data cutoff • 2 patients had Gr ≥3 TEAEs related to FT576: − 1
Slide 13: FT576: Phase 1 Dose Escalation Schema
FT576: Phase 1 Dose Escalation Schema Single- and Multi-dose Schedule as Monotherapy and in Combination with CD38-targeted mAb FT576 Monotherapy and FT576 + CD38-targeted mAb Combination Single-dose Cycle Two-dose Cycle Three-dose Cycles 100M Cells Ongoing Dose Potential Dose Escalation Escalation 3
Slide 14: FT522: Multi-antigen Targeted CAR NK Cell Product Candidate
FT522: Multi-antigen Targeted CAR NK Cell Product Candidate Targeting CD19 and CD20 for B-cell Lymphoma hnCD16 CD20-targeted Multi-antigen targeting monoclonal antibody • CD19: CAR construct targeting CD19 ADR • CD20: proprietary hnCD16 receptor designed to augment CAR-CD19 antibody-dependent cellul
Slide 15: FT522: Synthetic ADR Receptor to Increase NK Cell Potency
FT522: Multi-antigen Targeted CAR NK Cell Product Candidate Synthetic ADR Receptor to Increase NK Cell Potency and Reduce Patient Conditioning ADR-armed, iPSC-derived CAR NK cells selectively deplete alloreactive immune cells expressing 4-1BB Williams et al. 2022 ASH Annual Conference - 15 -
Slide 16: FT522: Synthetic ADR Receptor to Increase NK Cell Potency
FT522: Multi-antigen Targeted CAR NK Cell Product Candidate Synthetic ADR Receptor to Increase NK Cell Potency and Reduce Patient Conditioning While alloreactive immune cells expressing 4-1BB are selectively depleted, ADR-armed, iPSC-derived CAR NK cells are potentiated and expand Williams et al. 20
Slide 17: FT522: Maintains Potent CAR Activity In Vitro in Allogeneic Background
FT522: Multi-antigen Targeted CAR NK Cell Product Candidate Maintains Potent CAR Activity In Vitro in Allogeneic Background Tri-Culture MLR Setup iNK cells In a tumor cell restimulation assay, FT522 maintains potent CAR B2M KO Nalm6-luc Primed Allo T cells Daily dose activity alone and during alloge
Slide 18: FT522: IND Cleared; First Patient Dosing Targeted 2H23
FT522: Multi-antigen Targeted CAR NK Cell Product Candidate IND Cleared; Targeting Dosing of First Patient in 2H23 for r/r B-cell Lymphoma FT522 + CD20-targeted mAb Combination Three-dose Treatment Cycle Cy / Flu Conditioning Up to 3x first Up to 9x first 3 x 300M Cells Chemotherapy dose level / dos
Slide 19: iPSC-derived CAR T-cell Programs for Cancer
iPSC-derived CAR T-cell Programs for Cancer - 19 -
Slide 20: FT819: Off-the-Shelf CAR19 T-Cell Product Candidate
FT819: Off-the-Shelf CAR19 T-Cell Product Candidate Collaboration with Memorial Sloan Kettering Cancer Center First-of-Kind Off-the-Shelf CAR T-cell Therapy Derived from Renewable Master iPSC Line Engineered to Uniformly Express Novel 1XX CAR19 and Knock-out TCR 1XX CAR19: Novel chimeric antigen rec
Slide 21: FT819: Enhanced Tumor Control vs. Primary CAR T Cells
FT819: Enhanced Tumor Control vs. Primary CAR T Cells Disseminated Xenograft Model of Lymphoblastic Leukemia FT819 Consists of Memory Phenotype and Outcompetes Primary CAR T Cells In Vivo Valamehr et al. 2022 IO360 Annual Conference - 21 -
Slide 22: FT819: Clinical Responses in Aggressive B-cell Lymphoma
FT819: Off-the-Shelf CAR19 T-Cell Product Candidate Clinical Responses in a Difficult to Treat Aggressive B-cell Lymphoma Population Baseline Characteristics • Patients were heavily pre-treated with median of 5 prior lines of therapy (range 3-8) • 7 patients (5 with DLBCL, 1 with HGBCL, and 1 with G
Slide 23: FT819: Phase 1 Study in B-cell Lymphoma and CLL
FT819: Off-the-Shelf CAR19 T-Cell Product Candidate Phase 1 Study in Aggressive B-cell Lymphoma and Chronic Lymphocytic Leukemia FT819 Monotherapy: Single-dose Cycle Aggressive B-cell 90M Cells 180M Cells 360M Cells 540M Cells Up to 1B Cells Lymphoma Dose escalation ongoing at 540M cells Chronic Lym
Slide 24: Off-the-shelf Cell-based Cancer Immunotherapies for Solid Tumors
Off-the-shelf Cell-based Cancer Immunotherapies for Solid Tumors Developing Multiplexed-engineered, iPSC-derived Synthetic Killer Cells for Solid Tumors • Developing next-generation cancer immunotherapies must address numerous challenges that limit the effectiveness of today’s agents in treating sol
Slide 25: ONO Cancer Immunotherapy Collaboration
ONO Cancer Immunotherapy Collaboration Off-the-shelf, iPSC-derived CAR NK Cell and CAR T-Cell Collaboration for Solid Tumors Oncology Innovation for Solid Tumors • Proprietary antigen binding domains contributed by Ono • Multiplexed-engineered, CAR-targeted product candidates • Incorporating multipl
Slide 26: FT825/ONO-8250: iPSC-derived CAR T-cell for Solid Tumors
FT825/ONO-8250: iPSC-derived CAR T-cell for Solid Tumors Incorporates Seven Novel Synthetic Controls of Cell Function CAR-HER2: Novel 1XX CAR targeting HER2; controlled by hnCD16a TRAC locus IL7RF CXCR2 TCR KO: Complete loss of TCR surface expression to eliminate CAR-HER2 TGFβ Redirect potential of
Slide 27: FT825/ONO-8250: Differentiated Tumor-Targeting Activity
FT825/ONO-8250: iPSC-derived CAR T-cell for Solid Tumors Differentiated Tumor-Targeting Activity Robust HER2 Targeting Across a Wide Range of Antigen Expression Density Target cells FT825 hnCD16 Synthetic Control Enables Potential for Multi-antigen Targeting Target cells + mAb CAR iT cells + mAb FT8
Slide 28: FT825/ONO-8250: Synthetic Controls for Trafficking and TME Resistance
FT825/ONO-8250: iPSC-derived CAR T-cell for Solid Tumors Novel Synthetic Controls to Promote Trafficking and Resistance to TME Suppression Resistance to TGFβ Suppression over Multiple Rounds CXCR2 Expression Enables Ligand- of Tumor Challenge specific Migration Hosking et al. 2022 SITC Annual Confer
Slide 29: FT825/ONO-8250: In Vivo Anti-Tumor Activity
FT825/ONO-8250: iPSC-derived CAR T-cell for Solid Tumors In Vivo Anti-Tumor Activity as Monotherapy and in Combination In Vivo Anti-tumor Activity by CAR and by CAR+hnCD16 Aggressive subcutaneous xenograft model of ovarian cancer trastuzumab CAR iT cells FT825 FT825 + trastuzumab Vehicle Hosking et
Slide 30: First-in-class Cell Products for Autoimmunity
First-in-class Cell Products for Autoimmunity - 30 -
Slide 31: Cell-based Immunotherapies for Autoimmunity
Cell-based Immunotherapies for Autoimmunity Clinical Proof-of-Concept with Autologous CD19-targeted CAR T-cell Therapy Schett et al., 28, 2124-2132 (2022) • Systemic lupus erythematosus (SLE) patients with moderate / severe disease refractory to immunosuppressive drug treatments (n=5) • Rapid clinic
Slide 32: FT522: Product Configuration for Severe Autoimmune Diseases
FT522: Multi-antigen Targeted CAR NK Cell Product Candidate Unique Product Configuration for Addressing Severe Autoimmune Diseases • FT522 contains a series of unique targeting capabilities for the treatment of autoimmunity and inflammation SLE cells are CD19+ / CD20+ / CD38+ – NK cell: has activati
Slide 33: In Vitro B-cell Depletion in SLE PBMCs
Cell-based Immunotherapies for Autoimmunity In Vitro B-cell Depletion in Systemic Lupus Erythematosus (SLE) PBMCs SLE PBMCs CAR19 T FT522 FT819 Unpublished data of Fate Therapeutics - 33 -
Slide 34: Corporate Highlights
Corporate Highlights - 34 -
Slide 35: Fate Therapeutics: Changing the Game in Cell Therapy
Fate Therapeutics Changing the Game in Cell Therapy >200 Patients 40,000sf GMP treated with iPSC-derived NK and T in-house manufacturing facility cells across hematologic designed to US and international malignancies and solid tumors commercial standards Established Leadership Position for Off-the-s
Slide 36: Better Cells For Better Therapies
Better Cells For Better Therapies™ - 36 -
Fate Therapeutics — Investor Presentation (August 2023) on 6ix